PI-88 in Hepatocellular Carcinoma After Hepatectomy

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.

Clinical Trial Description

Although early diagnosis and treatment improve survival, hepatocellular carcinoma (HCC) is rarely cured and recurs frequently after regional therapy or transplantation. Hepatic resection can improve 5-year recurrence-free survival by up to 25%. Micrometastases of HCC have been detected by molecular techniques in 88% of patients at the time of surgery, and probably cause postoperative recurrence. Efforts to reduce the risk of recurrence after a curative resection have been tried, including various regimens of adjuvant and neoadjuvant therapy. In this study , an anti-angiogenic agent, PI-88, is being used as an adjuvant therapy for HCC patients after curative hepatic resection. The efficacy endpoints, including tumour non-recurrence rate, time to first recurrence and 1-year survival rate are being evaluated. Several risk factors associated with tumour recurrence are also being analysed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00247728
Study type	Interventional
Source	Cellxpert Biotechnology Corp.
Contact
Status	Completed
Phase	Phase 2
Start date	June 2004
Completion date	June 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03289533` - A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)	Phase 1
Terminated	`NCT01141478` - Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria	N/A
Recruiting	`NCT05580835` - PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma	N/A
Active, not recruiting	`NCT05389527` - Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma	Phase 2
Not yet recruiting	`NCT04560751` - TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Withdrawn	`NCT02939807` - A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	Phase 2
Completed	`NCT01915602` - Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)	Phase 2
Completed	`NCT04970212` - Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Recruiting	`NCT02403544` - Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma	Phase 1
Completed	`NCT01897038` - A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma	Phase 1
Terminated	`NCT01337492` - Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)	Phase 0
Terminated	`NCT01020812` - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Phase 1/Phase 2
Completed	`NCT01012011` - Regulatory Post Marketing Surveillance Study on Nexavar®	N/A
Completed	`NCT01003015` - Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma	Phase 2
Completed	`NCT00559455` - Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT00384800` - A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)	Phase 2
Terminated	`NCT00582400` - A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver	Phase 2
Completed	`NCT00056992` - Testing of ADI-PEG in Hepatocellular Carcinoma	Phase 2
Completed	`NCT02859324` - A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)	Phase 1/Phase 2
Terminated	`NCT02439008` - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response	N/A